We are very honoured to welcome Tetsuhiro Harimoto on the 23rd of February at MERLN.
Tetsuhiro Harimoto received his B.S. in Biomedical Toxicology from the University of Toronto in 2014. Following graduation, he worked as an Equity Research Associate at Morgan Stanley, focusing on the pharmaceutical and medical device industries. Tetsuhiro then completed his Ph.D. in Biomedical Engineering at Columbia University, working with Dr. Tal Danino, where he focused on the genetic engineering of microbes as novel drug delivery systems. Since 2022, Tetsuhiro has worked with Dr. David Mooney as an NCI F99/K00 postdoctoral fellow at the Wyss Institute for Biologically Inspired Engineering at Harvard University. His research focuses on developing engineered living materials as next-generation drug delivery systems. Tetsuhiro was recognized as one of STAT’s Wunderkinds and named to MIT Technology Review’s Innovators Under 35 in 2023.